InsidersTradesSigma
Browse the complete record of transactions filed by Spellman David A, Chief Financial Officer. Director active across 1 companies, notably Akebia Therapeutics, Inc.. Aggregated, 2 disclosures have been published. Total volume traded: €14k. The latest transaction was disclosed on 8 June 2022 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
2 of 2 declarations
Spellman David A is Chief Financial Officer, Senior Vice President, and Treasurer at Akebia Therapeutics, Inc. In this role, he is responsible for the company's financial management, including financial planning, risk management, and financial reporting. His expertise in finance enables him to support the company's growth strategy while ensuring regulatory compliance and financial transparency.